Form 4: Marimed COO Timothy Shaw Reports Significant Equity Holdings and RSU Grant

Marimed Inc.'s Chief Operating Officer, Timothy Shaw, has reported his direct and indirect beneficial ownership of common stock, alongside the grant of 245,316 Restricted Stock Units set to vest in three installments through December 2025.

Summary

• Timothy Shaw, Chief Operating Officer of Marimed Inc. (MRMD), reported his beneficial ownership of company securities.
• He directly owns 8,875,924 shares of common stock.
• An additional 2,000,000 shares of common stock are indirectly owned through the Shaw Family Trust, though Mr. Shaw disclaims beneficial ownership of these shares.
• Mr. Shaw was granted 245,316 Restricted Stock Units (RSUs) on May 23, 2025.
• These RSUs will convert to common stock on a one-for-one basis and will vest in three equal installments on June 15, 2025, September 15, 2025, and December 15, 2025.

Sentiment

Score: 7

Explanation: The grant of RSUs to a key executive is generally a positive signal, indicating alignment of interests and retention efforts, though a Form 4 is primarily a factual disclosure of transactions rather than a performance report.

Positives

• The grant of 245,316 Restricted Stock Units (RSUs) to the Chief Operating Officer aligns management incentives with shareholder value.
• The vesting schedule for RSUs over several months indicates a commitment to long-term retention of a key executive.

Future Outlook

The grant of Restricted Stock Units with a vesting schedule extending through December 2025 indicates a future alignment of executive incentives with long-term company performance and shareholder value creation.

Management Comments

• Timothy Shaw disclaims beneficial ownership of the 2,000,000 shares held by the Shaw Family Trust, stating his spouse is the trustee and the shares are for the benefit of his children, and the trust is irrevocable.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, common across all publicly traded companies. The grant of RSUs is a standard form of executive compensation, particularly in growth-oriented industries like cannabis (given Marimed's ticker MRMD), aiming to retain talent and incentivize performance.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as a form of executive compensation is a common practice across various industries, including the cannabis sector.
• While specific compensation packages vary by company size, performance, and executive role, RSUs are widely used to align executive interests with long-term shareholder value.
• Similar equity-based compensation structures are observed in companies like Curaleaf Holdings, Inc. (CURA), Green Thumb Industries Inc. (GTII), and Trulieve Cannabis Corp. (TRUL), which also utilize stock options and RSU grants to incentivize their leadership teams.
• The one-for-one conversion and multi-installment vesting schedule are standard features designed to promote retention and performance over time.

Related Party Transactions

• Timothy Shaw's indirect ownership of 2,000,000 shares through the Shaw Family Trust, where his spouse is the trustee and the shares benefit his children, constitutes a related party arrangement, though he disclaims beneficial ownership.

Stakeholder Impact

• Shareholders: The grant of RSUs to a key executive aligns management's interests with shareholder value creation, potentially leading to improved long-term performance.
• Employees: The RSU grant to the COO may signal a commitment to executive retention and a standard compensation practice within the company.

Next Steps

• Vesting of 245,316 Restricted Stock Units in three equal installments on June 15, 2025, September 15, 2025, and December 15, 2025.

Key Dates

Keywords

Marimed Inc., MRMD, Timothy Shaw, Chief Operating Officer, COO, SEC Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Units, RSU, Equity Grant, Executive Compensation